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Abstract
The resident microbial community, harboured by humans in sites such as the skin and gastrointestinal
tract, is enormous, representing a candidate environmental factor affecting susceptibility to complex dis-
eases, where both genetic and environmental risk factors are important. The potential of microorganisms
to influence the human immune system is considerable, given their ubiquity. The impact of the
hostgenemicrobe interaction on the maintenance of health and the development of disease has not
yet been assessed robustly in chronic inflammatory conditions. PsA represents a model inflammatory
disease to explore the role of the microbiome because skin involvement and overlap with IBD implicates
both the skin and gastrointestinal tract as sources of microbial triggers for PsA. In parallel with genetic
studies, characterization of the host microbiota may benefit our understanding of the microbial contribu-
tion to disease pathogenesis—knowledge that may eventually inform the development of novel
therapeutics.
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Introduction
The term microbiome has been used to describe the
microorganisms that are present on and in the human
body along with their genetic information and their ecolo-
gical milieu [1]. The human body harbours 10 times more
microbial cells than human cells and there is increasing
acknowledgement that this represents a second genome,
which contributes to tissue homeostasis [2]. The term
metagenome takes into account the contribution of the
genetic material from the host and all the genes and gen-
etic elements of the microorganisms in and on the host.
Metagenomics refers to the study of the structure of the
complex communities of the microbial flora inhabiting the
human host, the functional information about these com-
munities and the interactions with the human host [3]. The
National Institutes of Health (NIH) Human Microbiome
Project has endeavoured to characterize and establish a
standardized reference database of the human micro-
biome in healthy individuals [48] in an effort to under-
stand the interactions of microorganisms with the human
host in health. The goals of all the studies characterizing
the human microbiome are to define the complex micro-
bial community and explore their functional conse-
quences in human health and, ultimately, to translate
this to understanding disease.
The emerging impact of the microbiome
in inflammatory disorders
Indeed, hostmicrobegene interactions have been impli-
cated in the pathogenesis of inflammatory disorders [3].
The hypothesis is that the normal immune system de-
velops through harmonious relationships between the
host and the normal microbes. An imbalance in the
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immune system due to genetic variation thus leads to in-
appropriate levels of inflammation in response to micro-
bial products either as a failure to establish the normal
microbial flora or because of the presence of a key organ-
ism that triggers pathology [9]. The mutual effect of the
human immune system on the composition of the micro-
biota and the effect of the microbiota on the immune
system is well described [10].
In terms of inflammatory arthritic diseases, Costello
et al. [11] have discussed the potential role of the gut as
a physical as well as an immune barrier in AS and the
impact of the gut microbiota on disease. A recent study
[12] comparing the faecal microbiota in early RA with
those seen in FM reported a difference in the faecal bac-
terial composition but was limited by the number of bac-
terial species that could be investigated. The studies, to
date, have been cross-sectional in nature and have not
been able to determine whether changes in the micro-
biome are cause or effect. To determine the causality of
an observational analysis of the human microbiome
requires evidence of the consistency, specificity, tempor-
ality and biological plausibility of a relationship. The ex-
emplar is the discovery and eradication of Helicobacter
pylori, which changed the management of peptic ulcer
disease and demonstrated the pathogenic role of this
bacterium. Nonetheless, even cross-sectional metage-
nomic studies will inform hypotheses about causality.
Advances in technology mean it is now possible to effi-
ciently study the community structure and characterize
the functional metagenomics of this important, potentially
modifiable, environmental factor.
Recent technological advances in the
investigation of the microbiome
Studying the microbiome was previously limited to cul-
ture-dependent methods that resulted in difficulties in iso-
lating and identifying the fastidious (difficult to culture)
microbes. Culture-independent methods of microbial
identification are usually based on characterizing the bac-
terial flora by sequencing of the 16S rRNA gene. The 16S
rRNA gene is found in all bacteria, but not in human cells;
it is highly conserved with nine hypervariable regions
(V1V9) that can be used to determine the species of
the bacteria. It is large enough (1500 bp) for informatics
purposes, and the function of the gene has not changed
substantially over time, which means that any changes
within the gene reflect new mutations or evolution.
Culture-independent methods have facilitated the identifi-
cation of even the most fastidious bacteria and, conse-
quently, have significantly expanded the numbers of
bacteria identified in a wide range of environmental and
clinical niches.
All sequencing-based methods use primers that bind to
the unique DNA sequence within or around the 16S rRNA
gene. Thus all amplification products should be of bacter-
ial, not human, origin. The length of the amplified se-
quence depends on the site of primer binding, and this
is determined by the primers used. The bacterial DNA
sequence can then be determined using a choice of
platforms. Metzker [13] has elegantly described the
sequencing technologies that are currently available. The
first-generation technology, employing automated Sanger
sequencing, is slow and relatively expensive, but pro-
duces long reads (segments of DNA that are being ana-
lysed). The advantage of sequencing the entire 16S rRNA
gene using the Sanger sequencing technology is that it
reduces the possibility of primer bias (selective loss of
bacterial groups due to the inability to accurately se-
quence certain bacteria because of the region that the
selected primer pair binds), which may be introduced in
the newer next-generation sequencing (NGS) platforms,
such as the Roche/454 GS Junior, Illumina/MiSeq and
Life Technologies/Ion Torrent PGM. The newer NGS plat-
forms are faster and more cost effective, but they have
shorter mean read lengths of DNA (between 150 and 550
bases).
However, for taxonomic assignment of bacteria using
the 16S rRNA gene, read lengths as small as 250 bp
have been shown to be sufficient, with relatively little
benefit in increasing the read length [14]. The shorter
read lengths that are the norm of the NGS platforms
have the disadvantage that, depending on the hypervari-
able region selected for amplification, not all groups of
bacteria can be classified. Conversely, NGS technologies
have a greater depth of sequencing (with larger number of
reads) and in general have lower sequencing errors.
Hence the choice of platform is moving towards NGS,
especially with the increasing read lengths that all pro-
viders are striving to achieve and approaches that com-
bine data generated using a collection of primers targeting
several variable regions. The use of barcodes in NGS
allows pooling of samples, facilitating analysis of larger
numbers of samples simultaneously. NGS technologies
are being extensively used in the investigation of the
microbiome [6, 7, 14, 15], including the NIH Human
Microbiome Project [4].
Aetiological hypothesis: PsA and the
microbiome
Psoriasis is a chronic inflammatory skin condition that is
prevalent worldwide, with varying incidence and preva-
lence rates depending on the geographic region and age
group studied [16]. Nearly one-third of individuals with
psoriasis develop PsA, with an average of 810 years
from the onset of skin disease [1723]. Studies have
shown that patients with PsA have greater cardiovascular
morbidity than the general population [24] and poor qual-
ity of life [25]. Given these co-morbidities, it is imperative
that early effective intervention is instituted in patients with
PsA. However, the treatment of PsA patients is often
based on knowledge and evidence from studies investi-
gating patients with RA. A recent study [26] exploring the
synovial histopathology of PsA compared with undifferen-
tiated spondyloarthropathy (USpA), AS and RA showed
that PsA is more similar to USpA and AS than RA.
These discrepancies highlight the need to understand
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the pathogenesis of PsA for development of targeted
therapies.
The 40-fold increased recurrence risk ratio observed by
Karason et al. [27] in first degree relatives of patients with
PsA suggests a strong and complex genetic susceptibility
component along with an important environmental contri-
bution. Among the environmental triggers, infections have
been investigated as infectious triggers of PsA in the past.
For example, Vasey et al. [28] found elevated levels of
antibody to streptococcal exotoxin anti-deoxyribonucle-
ase-B in PsA compared with patients with psoriasis with-
out arthritis, RA or other forms of dermatitis and normal
controls. In a study that investigated surrogate markers for
viral infection, an increased incidence of serological mar-
kers for HCV in PsA cases compared with patients with
RA have been reported [29], although the finding was not
replicated in a later study [30].
More recently, Eder et al. [31] reported the association
of infection requiring antibiotic treatment with the onset of
PsA in a casecontrol study. With the advent of the HIV
epidemic in sub-Saharan Africa and the de novo appear-
ance of psoriasis and PsA in a population with previously
low incidence and prevalence rates [32, 33], there is re-
newed interest in the dysregulation of innate immunity due
to infection or an alteration in the microbial community
structure as an aetiological pathway.
However, the identification of a clear-cut contribution
from a pathogen to PsA susceptibility has been elusive.
Histologically there is evidence of inflammation in the gut
[34, 35] and psoriatic skin lesions [36], therefore the pos-
sibility of variations in the microbiological milieu at these
sites of immune regulation has been considered. Support
for involvement of the skin microbiome comes from re-
ports of overexpression of endogenous antimicrobial pep-
tides such as cathelicidins [36] and human beta-defensin
2 (hBD-2) [37] in psoriatic skin lesions, and simultaneously
increased serum HBD-2 levels have been found in active
psoriatic skin disease [37]. High hBD-2 levels have an
immune-modulatory effect as well as chemotactic proper-
ties [37].
Furthermore, a recent review [38] of the functional and
genetic studies in psoriasis and PsA have implicated
genes affecting the skin barrier function, as well as the
innate and adaptive immune systems in the pathogenesis
of these diseases. Such studies add to the increasing evi-
dence of the influence of the IL-23/IL-17 axis in psoriasis
[39] and PsA [40], and the advent of effective treatments
targeting the downstream IL-17 cytokine implicates the
central role of the Th17 subset of T cells.
Interestingly, Ivanov et al. [41] demonstrated the import-
ance of local microbiota in driving the Th17 cell repertoire
and maintaining the balance between regulatory T cells
(Treg) and Th17 cells in the gut, while Belkaid et al. [42]
demonstrated the importance of local cutaneous micro-
biota in the modulation of T cell effector function in germ-
free and specific-pathogen-free mice: administration of an
antibiotic cocktail to the mice did not affect the skin
microbiota but did affect the gut. In germ-free mice the
introduction of a skin commensal rescued the IL-17A
production in the skin but not in the gut. Restoration of
the immune response in germ-free mice by introduction of
a skin commensal underlines the importance of the
hostskincommensal cross talk.
The skin microbiome is therefore being investigated to
assess the hostmicrobe symbiotic relationship and to
gain an understanding of its contribution to the pathology
of skin diseases [43]. As PsA develops in individuals with
psoriasis, examining the difference in skin microbe com-
position in those who develop PsA and those who do not
may offer unique insights into its pathogenesis. This infor-
mation may also help in stratifying individuals who may be
predisposed to developing arthritis from among the psori-
atic group. The potential for the discovery of variations
in the pathogenesis depending on the combined
hostmicrobiome characteristics may contribute to im-
proving our understanding of the underlying mechanism
of the disease in different subgroups and could ultimately
lead to potential therapeutic targets for prevention and
control of PsA.
Investigation of the skin microbiome:
progress so far
Skin, the largest organ of the human body, is a complex
and dynamic ecosystem hosting a multitude of microor-
ganisms and is one of the main physical barriers of de-
fence in humans. The interactions occurring in the skin, as
an organ, include those between the human host cells,
external microbes, other environmental factors and the
existing resident microbial components. Cogen et al.
[44] describe the various positive (where both species
benefit) and negative (where one species benefits at the
cost of the other) potential relationships between the skin
flora and the human host. Technically the skin microbiome
is the most challenging microbial milieu to study due to
the difficulty of DNA extraction from a low bacterial bio-
mass. Table 1 describes the main features of previous
studies of the skin microbiome using culture-independent
methods. These studies compared the skin microbiome
between populations of different ethnicities and regions,
between healthy and diseased skin, have explored inter-
and intra-personal variation of the skin microbiome, have
assessed differences between various sampling and DNA
extraction techniques and consequently have established
a database of the healthy core skin microbiome.
Different techniques of sampling of the skin micro-
biome, namely skin swabs, scrapes and punch biopsies,
have been assessed [45]. All three methods were able to
capture a representative profile of the microbial commu-
nity. Robust statistical analysis supported the existence of
a core skin microbiome among healthy human subjects. In
a follow-up study, the microbiome from 20 distinct skin
sites in healthy individuals was analysed and showed that
physiologically comparable sites harbour similar bacterial
communities, but sebaceous skin sites are less diverse,
less even and less rich than moist and dry sites [46].
The temporal variation of the skin microbiome has been
explored in several studies [4650]. Although the time
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intervals varied from a few hours to several months, dif-
ferent methodologies were employed and the sites inves-
tigated varied in these studies, the skin microbiome was
found to be stable in an individual over time. Furthermore,
analysis of two analogous sites (left and right side of the
body) [49] showed a high level of conservation of the bac-
terial community at any moment in time. The more exten-
sive sample size from the Human Microbiome Project [51]
is now providing the database for the core microbiome of
healthy humans. In that study, the core operational taxo-
nomic units (OTUs; defined as the number of distinct 16S
rRNA sequences at a certain cut-off level of sequence
diversity) were defined as those that were present in at
least 95% of all the samples for a given body site. The
relative abundance (840.021%) of the core OTUs varied
between subjects, but the notable feature was that the
most abundant OTUs tend to be present in more subjects
than the less abundant OTUs overall.
Preliminary assessment of psoriatic plaques has shown
that there is a difference in the skin microbiome between
the plaques and the normal skin in individuals with psor-
iasis [52]. The Blaser lab [52] compared the microbiota in
psoriatic plaques with that of normal skin in six individuals
with psoriasis and also the normal skin in six healthy con-
trols. Fahlen et al. [53] compared the skin biopsies from
psoriasis plaques from 10 individuals with psoriasis with
skin biopsies from control individuals undergoing wide ex-
cision of skin lesions without any past or family history of
psoriasis. Both studies found similar results, with
increased Firmicutes (one of the major bacterial phyla
including most of the Gram-positive genera) in the psori-
atic plaques and a higher ratio of Streptococcus/
Propionibacterium in the psoriatic plaques compared
with controls. Some differences between the studies
were noted, but were thought to arise because of vari-
ations in the sampling methods and the unmatched
nature of the control skin obtained for analysis in the
study conducted by Fahlen et al. [53]. In both studies,
psoriasis patients had stopped topical treatment for at
least 2 weeks prior to the sampling and were not on any
systemic treatment, thereby reducing the possibility of
treatment confounding the results.
Non-invasive skin swabs were the sampling method of
choice in most studies. However, the yield of bacterial
DNA from swabs can be low, reflecting the low biomass
of the bacteria resident on the skin. Several DNA extrac-
tion techniques have been used and Flores et al. [54]
compared the direct PCR approach against the DNA ex-
traction/purification approach to determine if yields were
similar. The consensus was that the direct approach was
faster but resulted in lower bacterial yields, so it may not
be appropriate if multiple PCR-based assays are required.
However, the newer, commercially available DNA extrac-
tion kits have improved the yield of bacterial DNA from
skin swabs.
The PCR primers used in the different studies varied
with respect to the regions selected for amplification in
the 16S rRNA gene. The majority of the published studies
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regions in the 16S rRNA gene. The latest studies [51, 53,
54] have restricted the choice of region to V3V5. This is
because sequences from the V3V5 primers were signifi-
cantly more accurate relative to data generated from
V1V3 or V6V9 primers when tested using the Roche
454 platform [55]. The primary NGS platform to be utilized
for microbial work was the Roche 454, due to its ability to
produce long maximum (1000 bp) read lengths; when this
platform was used, the sample size studied was greatly
increased (a few hundred individuals) compared with the
use of Sanger sequencing technologies (tens of subjects).
The cost, throughput, speed, flexibility and high volume of
data output of the newer benchtop sequencers (MiSeq,
Ion Torrent), although generating shorter read lengths, are
promising and warrant their use in larger-scale studies
to provide greater power.
Discussion
The studies that are currently available in the literature
with respect to the skin microbiome are limited in
number. The majority have attempted to assess the
normal skin microbiome using culture-based methods
and to answer basic questions regarding the spatial and
temporal association and stability of the microbiological
milieu. The Human Microbiome Project is now developing
a database of the core microbiome of different ecological
niches of the human body. The temporal stability of the
microbiome has been demonstrated and studies have as-
certained the existence of differing microbial communities
in the different ecological niches of the skin. This informa-
tion is important to enable characterization of the normal
composition of the microbiome. The studies that have
looked at disease conditions have shown variations from
the normal in a number of conditions. Further work needs
to be done to build upon these important results. The
establishment of causality of a microorganism would re-
quire replication of previous work and further detailed
functional characterization of the microbiome.
The explosion in NGSs will certainly be helpful for
undertaking high-throughput parallel sequencing at a
reduced cost and should pave the way for genotypic
and functional characterization of the complex microbial
communities in a relatively short time. However, being
aware of the shortcomings of these methods, namely
short read length, primer bias, sequencing errors and
depth of sequencing in the different methods employed,
is essential to develop robust databases. The Human
Microbiome Project has attempted to standardize proced-
ures to enable researchers worldwide to replicate and
continue to expand this work. Computational capacity
and constant improvements in the pipelines available for
the analysis of the immense datasets generated by high-
throughput sequencers is an essential requirement for
obtaining valid data. This latter aspect is currently the bot-
tleneck in many studies and is a problem that requires
concerted effort in terms of development of user-friendly
tools for data analysis and wider training of suitably qua-
lified personnel.
Just as knowledge of the inflammatory pathways in RA
paved the way for the use of the biologic anti-TNF treat-
ments, knowledge of the skin microbiome in PsA may be
the first step towards future progress in therapeutics and
early identification. Our current knowledge of the skin
microbiome in psoriasis suggests an alteration in the micro-
biota of psoriatic plaques. Investigation of the psoriatic
plaques in PsA will determine if there is further compromise
in the skin barrier that may explain the drivers of inflamma-
tory arthritis. This may also help in developing strategies for
PsA prevention in patients with psoriasis or delaying the
onset of joint disease. Extending the application to charac-
terization of the microbiome in the gut and determination
of the microbial variation between inflammatory bowel
disease with or without PsA may also be enlightening.
In comparing psoriasis and PsA, however, potential
confounders such as therapy, ultraviolet light exposure
and skin type pose a challenge to the interpretation of
these findings. Functional characterization work through
metatranscriptomic studies, such as those currently being
undertaken in the NIH Human Microbiome Project, will
help to clarify the significance of microbial flora. As
described by Grice and Segre [2], characterizing and
analysing the human microbiome is vital for an under-
standing of this essential yet overlooked component of
human immune regulation and important contributor to
tissue metabolism and homeostasis. Defining the role of
the microbiome in complex diseases like PsA, which has a
very strong genetic contribution, but where the causality
cannot be explained solely by host genetics, has the
potential to impact our understanding of the disease
pathogenesis.
Rheumatology key messages
. The skin microbiome is an intriguing candidate
environmental factor in PsA.
. Different approaches have been used to study the
skin microbiome, and each has its strengths and
weaknesses.
. 16S rRNA gene sequencing is ideal for bacterial
microbiome hypothesis generation in PsA.
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